Product image of Linagliptin Sandoz (Linagliptin) supplied by GNH India

Linagliptin Sandoz

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Sandoz (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Sandoz, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, often in combination with diet, exercise and other antidiabetic agents.

GNH India supplies Linagliptin Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand, including temperature‑controlled logistics where required.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers blood glucose when used alone.
  • Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control when combined with metformin.
  • Type 2 diabetes mellitus (add‑on to insulin): improves post‑prandial glucose when combined with insulin therapy.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, thereby reducing blood glucose concentrations in patients with type 2 diabetes.

Side Effects

Adverse reactions reported with linagliptin vary in frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection.
  • Headache: transient mild to moderate pain.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal upset: nausea or abdominal discomfort.
  • Back pain: intermittent musculoskeletal discomfort.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.
  • Bullous skin reactions: blistering skin conditions such as Stevens‑Johnson syndrome.
  • Severe cutaneous adverse reactions: toxic epidermal necrolysis.

Precautions & Warnings

When prescribing linagliptin, clinicians should consider the following precautions.

  • Renal impairment: monitor renal function; dose adjustment is not required but caution is advised.
  • Hepatic impairment: use with caution and monitor liver enzymes regularly.
  • Risk of hypoglycaemia: avoid or adjust concomitant insulin or sulfonylurea therapy.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks.
  • Elderly patients: monitor for adverse reactions due to possible comorbidities.
  • Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Avoid Interactions

Linagliptin may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia.
  • Drugs known to cause pancreatitis: additive risk of pancreatic inflammation.

Moderate Interactions (Monitor Closely):\n- Rifampin: may reduce linagliptin plasma concentrations.

  • Diuretics: monitor blood glucose as fluid shifts can affect glycaemic control.
  • ACE inhibitors: no significant interaction but renal function should be monitored.

Frequently Asked Questions

Linagliptin Sandoz contains the active ingredient linagliptin, a DPP‑4 inhibitor indicated to improve blood glucose control in adults with type 2 diabetes mellitus, either as a stand‑alone therapy or in combination with other antidiabetic agents.

Linagliptin selectively blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels.

The specific dose of Linagliptin Sandoz is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal and hepatic function, and any concomitant medications. Patients should follow the prescriber’s instructions exactly.

Safety data for linagliptin in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is distinguished by its primarily non‑renal elimination, which means dose adjustment is generally not required in patients with renal impairment, unlike some other DPP‑4 inhibitors that require dose reductions based on kidney function.

Linagliptin Sandoz tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children.

Linagliptin Sandoz is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, hepatic injury, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic response.

Linagliptin should be avoided in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with a history of pancreatitis, severe liver disease, or those taking medications that may cause serious drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT